Level 2 resilience sub-factors supporting inter-organizational, cross-sector and cross-border collaboration (ICC collaboration)
| Level 1 resilience sub-factors | Level 2 resilience sub-factors |
|---|---|
| Collaboration – product flow | Collaboration to build cold chain capacity, design air cargo logistics, transportation and last mile delivery |
| Collaboration to expand and improve supplier and manufacturer capacity and procurement | |
| Collaboration for vaccine R&D and regulatory approval | |
| Collaboration in cross-border management | |
| Collaboration to ensure vaccine safety, security and quality assurance | |
| Collaboration – financial flow | Government subsidization of manufacturing capacity |
| Government procurement of vaccines | |
| Multilateral and international organization funding of manufacturing capacity and procurement of vaccines | |
| Government subsidization of input manufacturing capacity | |
| Government subsidization of freight | |
| Collaboration – information flow | Collaboration for use of digital and advanced technologies to speed logistics operations |
| Cooperation in disseminating information for decision-making | |
| Collaboration in providing information to encourage immunization | |
| Collaboration – vaccine recipient flow | Collaboration in managing distribution and mass vaccination logistics |
| Ethical distribution of vaccines to remote and isolated vaccine recipients | |
| Collaboration – knowledge flow | Private sector collaboration to transfer technology |
| Collaboration – skilled worker flow | N/A* |
| Collaboration – waste flow | Cross-border collaboration to redeploy unused vaccines to other countries prior to expiry |
| Level 2 resilience sub-factors | |
|---|---|
| Collaboration to build cold chain capacity, design air cargo logistics, transportation and last mile delivery | |
| Collaboration to expand and improve supplier and manufacturer capacity and procurement | |
| Collaboration for vaccine R&D and regulatory approval | |
| Collaboration in cross-border management | |
| Collaboration to ensure vaccine safety, security and quality assurance | |
| Government subsidization of manufacturing capacity | |
| Government procurement of vaccines | |
| Multilateral and international organization funding of manufacturing capacity and procurement of vaccines | |
| Government subsidization of input manufacturing capacity | |
| Government subsidization of freight | |
| Collaboration for use of digital and advanced technologies to speed logistics operations | |
| Cooperation in disseminating information for decision-making | |
| Collaboration in providing information to encourage immunization | |
| Collaboration in managing distribution and mass vaccination logistics | |
| Ethical distribution of vaccines to remote and isolated vaccine recipients | |
| Private sector collaboration to transfer technology | |
| N/A* | |
| Cross-border collaboration to redeploy unused vaccines to other countries prior to expiry |
Note: *N/A – implies no references were coded to these nodes